Click here to view original web page at cen.acs.org
Denali Therapeutics has found a way to sneak biologics past the blood-brain barrier (BBB), suggests preliminary Phase I data of the firm’s DNL310 in Hunter syndrome. Hunter syndrome is a rare, lysosomal storage disorder caused by mutations in iduronate 2-sulfatase (IDS), an enzyme that degrades sugar molecules called glycosaminoglycans. […]